Pulmonary hypertension life expectancy and prognosis can vary broadly, but have improved in the era of modern treatment.

The study investigators wanted more data on long-term outcomes in pediatric patients following implantation of a transcatheter Potts shunt (TPS) for treatment of severe pulmonary arterial hypertension ...

The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved sotatercept (Winrevair, Merck Sharp & Dohme) as a new treatment to improve exercise capacity in patients with pulmonary ...

The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday. A novel activin signaling inhibitor, sotatercept is indicated to ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in combination with other pulmonary ...

Researchers in China report that a simple heart ultrasound measure of left ventricular underfilling is a valuable prognostic ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Pulmonary arterial hypertension (PAH) is a severe disease with poor prognosis and shortened life expectancy. Treatment has traditionally involved the sequential use of endothelin receptor agonists, ...